SEQUENCE LISTING

<110> Biotest AG
Dana-Farber Cancer Institute, Inc.
ImmunoGen, Inc.

<120> METHODS AND AGENTS FOR IMPROVING TARGETING OF CD138 EXPRESSING TUMOR CELLS

<130> 319932.WO/JND/CJS

<150> 61/016,614
<151> 2007-12-26

<150> 61/087,466
<151> 2008-08-08

<150> 61/087,590
<151> 2008-08-08

<160> 13

<170> PatentIn version 3.5

<210> 1
<211> 448
<212> PRT
<213> Artificial Sequence

<220>
<223> Amino Acid sequence (predicted) of heavy chain of chimeric human/mouse antibody

<220>
<221> CDR1
<222> (31)..(35)

<220>
<221> CDR2
<222> (51)..(68)

<220>
<221> CDR3
<222> (99)..(111)

<220>
<221> region IgG4
<222> (123)..(448)

<400> 1

Gln Val Gln Leu Gln Gln Ser Gly Ser Glu Leu Met Met Pro Gly Ala
1 5 10 15

Ser Val Lys Ile Ser Cys Lys Ala Thr Gly Tyr Thr Phe Ser Asn Tyr
20 25 30

Trp Ile Glu Trp Val Lys Gln Arg Pro Gly His Gly Leu Glu Trp Ile

```
        35                  40                  45

Gly Glu Ile Leu Pro Gly Thr Gly Arg Thr Ile Tyr Asn Glu Lys Phe
    50                  55                  60

Lys Gly Lys Ala Thr Phe Thr Ala Asp Ile Ser Ser Asn Thr Val Gln
65                  70                  75                  80

Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
                85                  90                  95

Ala Arg Arg Asp Tyr Tyr Gly Asn Phe Tyr Tyr Ala Met Asp Tyr Trp
            100                 105                 110

Gly Gln Gly Thr Ser Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro
        115                 120                 125

Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr
    130                 135                 140

Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr
145                 150                 155                 160

Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro
                165                 170                 175

Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr
            180                 185                 190

Val Pro Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp
        195                 200                 205

His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr
    210                 215                 220

Gly Pro Pro Cys Pro Ser Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro
225                 230                 235                 240

Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser
                245                 250                 255

Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp
            260                 265                 270

Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn
        275                 280                 285
```

```
Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val
    290                 295                 300

Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu
305                 310                 315                 320

Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys
                325                 330                 335

Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr
            340                 345                 350

Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr
        355                 360                 365

Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu
    370                 375                 380

Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu
385                 390                 395                 400

Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys
                405                 410                 415

Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu
            420                 425                 430

Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly
        435                 440                 445
```

<210> 2
<211> 214
<212> PRT
<213> Artificial Sequence

<220>
<223> Amino Acid sequence (predicted) of light chain of chimeric human/mouse antibody

<220>
<221> CDR1
<222> (24)..(34)

<220>
<221> CDR2
<222> (50)..(56)

<220>

<221> CDR3
<222> (89)..(97)

<220>
<221> region IgG4
<222> (108)..(214)

<400> 2

```
Asp Ile Gln Met Thr Gln Ser Thr Ser Ser Leu Ser Ala Ser Leu Gly
1               5                  10                  15


Asp Arg Val Thr Ile Ser Cys Ser Ala Ser Gln Gly Ile Asn Asn Tyr
            20                  25                  30


Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Glu Leu Leu Ile
        35                  40                  45


Tyr Tyr Thr Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
    50                  55                  60


Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Pro
65                  70                  75                  80


Glu Asp Ile Gly Thr Tyr Tyr Cys Gln Gln Tyr Ser Lys Leu Pro Arg
                85                  90                  95


Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala
            100                 105                 110


Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
        115                 120                 125


Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
    130                 135                 140


Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145                 150                 155                 160


Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
                165                 170                 175


Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
            180                 185                 190


Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
        195                 200                 205
```

Phe Asn Arg Gly Glu Cys
210

<210> 3
<211> 31
<212> DNA
<213> Artificial Sequence

<220>
<223> IgH primer MHV7

<400> 3
atgggcatca agatggagtc acagacccag g 31

<210> 4
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> IgG1 constant region primer MHCG1

<400> 4
cagtggatag acagatgggg g 21

<210> 5
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Ig kappa primer MKV2

<400> 5
atggagacag acacactcct gctatgggtg 30

<210> 6
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> Ig kappa primer MKV4

<400> 6
atgagggccc ctgctcagtt ttttggcttc ttg 33

<210> 7
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Ig kappa primer MKV9

<400> 7

atggtatcca cacctcagtt ccttg 25

<210> 8
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> primer MKC

<400> 8
actggatggt gggaagatgg 20

<210> 9
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> forward (For) primer

<400> 9
agagaagctt gccgccacca tgattgcctc tgctcagttc cttggtctcc 50

<210> 10
<211> 35
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide primer BT03

<400> 10
caacagtata gtaagctccc tcggacgttc ggtgg 35

<210> 11
<211> 35
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide primer BT04

<400> 11
ccaccgaacg tccgagggag cttactatac tgttg 35

<210> 12
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> primer g2258

<400> 12
cgcgggatcc actcacgttt gatttccagc ttggtgcctc c 41

<210> 13
<211> 45
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer g22949

<400> 13
cgatgggccc ttggtggagg ctgaggagac ggtgactgag gttcc 45